NEW YORK (GenomeWeb News) - Regeneron Pharmaceuticals has teamed with Geisinger Health System of Pennsylvania in a project that will use genomic analysis to study 100,000 patients with the aim of improving drug development and patient care capabilities, the partners said on Monday.

Regeneron will conduct its end of the partnership out of a new subsidiary, the Regeneron Genetics Center, located in Tarrytown, NY.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.